Terms: = Lung cancer AND WFDC2, EDDM4, HE4, WAP5, dJ461P17.6 AND Prognosis
20 results:
1. Factors influencing blood tumor marker concentrations in the absence of neoplasia.
Trapé J; Fernández-Galán E; Auge JM; Carbonell-Prat M; Filella X; Miró-Cañís S; González-Fernández C;
Tumour Biol; 2024; 46(s1):S35-S63. PubMed ID: 38517826
[TBL] [Abstract] [Full Text] [Related]
2. Relevance of tumor markers for prognosis and predicting therapy response in non-small cell lung cancer patients: A CEPAC-TDM biomarker substudy.
Geiger K; Joerger M; Roessler M; Hettwer K; Ritter C; Simon K; Uhlig S; Holdenrieder S
Tumour Biol; 2024; 46(s1):S191-S206. PubMed ID: 38363625
[TBL] [Abstract] [Full Text] [Related]
3. Comprehensive analysis of the lncRNAs-related immune gene signatures and their correlation with immunotherapy in lung adenocarcinoma.
Yang Z; Zhu J; Yang T; Tang W; Zheng X; Ji S; Ren Z; Lu F
Br J Cancer; 2023 Oct; 129(9):1397-1408. PubMed ID: 37543671
[TBL] [Abstract] [Full Text] [Related]
4. Secreted proteins MDK, wfdc2, and CXCL14 as candidate biomarkers for early diagnosis of lung adenocarcinoma.
Li J; Li J; Hao H; Lu F; Wang J; Ma M; Jia B; Zhuo M; Wang J; Chi Y; Zhai X; Wang Y; Wu M; An T; Zhao J; Yang F; Wang Z
BMC Cancer; 2023 Jan; 23(1):110. PubMed ID: 36721112
[TBL] [Abstract] [Full Text] [Related]
5. Development of exploratory algorithms to aid in risk of malignancy prediction of indeterminate pulmonary nodules.
Jeanblanc N; Jackson L; Gawel S; Brophy S; Vaidya S; Syed S; Davis GJ; Borgia JA
Clin Chim Acta; 2022 Oct; 535():197-202. PubMed ID: 36087784
[TBL] [Abstract] [Full Text] [Related]
6. Human epididymis protein 4 is associated with severity and poor prognosis of connective tissue disease-associated interstitial lung disease with usual interstitial pneumonia pattern.
Meng K; Tian M; Gui X; Xie M; Gao Y; Shi S; Zhao T; Xiao Y; Cai H; Ding J
Int Immunopharmacol; 2022 Jul; 108():108704. PubMed ID: 35413677
[TBL] [Abstract] [Full Text] [Related]
7. Diagnostic value of human epididymis protein 4 in malignant pleural effusion in lung cancer.
Lv M; Wang F; Wang X; Zhang C
Cancer Biomark; 2019; 26(4):523-528. PubMed ID: 31658049
[TBL] [Abstract] [Full Text] [Related]
8. [Analysis of the correlation between the expression of wfdc2 in B cells of lung adenocarcinoma tissue and the survival rate of patients].
Zhang H; Lu J; Yang Y; Wang L
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2019 May; 35(5):425-433. PubMed ID: 31223112
[TBL] [Abstract] [Full Text] [Related]
9. Potential for the blood-based biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymal protein 4 (he4) to detect recurrence during monitoring after surgical resection of adenocarcinoma of the lung.
Muley T; He Y; Rolny V; Wehnl B; Escherich A; Warth A; Stolp C; Schneider MA; Meister M; Herth FJ; Dayyani F
Lung Cancer; 2019 Apr; 130():194-200. PubMed ID: 30885344
[TBL] [Abstract] [Full Text] [Related]
10. Serum Human Epididymis Secretory Protein 4 (he4) is a Potential Prognostic Biomarker in Non-Small Cell lung cancer.
Mo D; He F
Clin Lab; 2018 Sep; 64(9):1421-1428. PubMed ID: 30274019
[TBL] [Abstract] [Full Text] [Related]
11. Preparation and characterization of a high-affinity monoclonal antibody against human epididymis protein-4.
Shen Y; Wang Y; Jiang X; Lu L; Wang C; Luo W; Zhang Y; Li P; Du Z; Dai T; Wu C; Fang A; Yao Y; Peng Q; Yang J
Protein Expr Purif; 2018 Jan; 141():44-51. PubMed ID: 28928083
[TBL] [Abstract] [Full Text] [Related]
12. he4 expression in lung cancer, a meta-analysis.
Zhong H; Qian Y; Fang S; Yang L; Li L; Gu W
Clin Chim Acta; 2017 Jul; 470():109-114. PubMed ID: 28499820
[TBL] [Abstract] [Full Text] [Related]
13. Human Epididymis Protein 4 (he4) in Patients with Small-Cell lung cancer.
Wojcik E; Tarapacz J; Rychlik U; Stasik Z; Sas-Korczynska B; Skotnicki P; Kulpa JK
Clin Lab; 2016 Sep; 62(9):1625-1632. PubMed ID: 28164590
[TBL] [Abstract] [Full Text] [Related]
14. Serum human epididymis protein 4 is associated with the treatment response of concurrent chemoradiotherapy and prognosis in patients with locally advanced non-small cell lung cancer.
Lan WG; Hao YZ; Xu DH; Wang P; Zhou YL; Ma LB
Clin Transl Oncol; 2016 Apr; 18(4):375-80. PubMed ID: 26329292
[TBL] [Abstract] [Full Text] [Related]
15. Serum he4: An Independent Prognostic Factor in Non-Small Cell lung cancer.
Lamy PJ; Plassot C; Pujol JL
PLoS One; 2015; 10(6):e0128836. PubMed ID: 26030627
[TBL] [Abstract] [Full Text] [Related]
16. [Advances of human epididymis protein 4 in lung cancer].
Ma Q; Wang Q; Zhong D
Zhongguo Fei Ai Za Zhi; 2015 Mar; 18(3):184-6. PubMed ID: 25800577
[TBL] [Abstract] [Full Text] [Related]
17. Serum biomarkers for assessing histology and outcomes in patients with metastatic lung cancer.
Lou E; Johnson M; Sima C; Gonzalez-Espinoza R; Fleisher M; Kris MG; Azzoli CG
Cancer Biomark; 2014; 14(4):207-14. PubMed ID: 24934363
[TBL] [Abstract] [Full Text] [Related]
18. Evaluating the clinical significance of serum he4 levels in lung cancer and pulmonary tuberculosis.
Liu W; Yang J; Chi PD; Zheng X; Dai SQ; Chen H; Xu BL; Liu WL
Int J Tuberc Lung Dis; 2013 Oct; 17(10):1346-53. PubMed ID: 24025389
[TBL] [Abstract] [Full Text] [Related]
19. Splice variant he4-V3 expression is associated with favorable prognosis in pulmonary adenocarcinoma.
Tokuishi K; Yamashita S; Ohbo K; Kawahara K
Tumour Biol; 2012 Feb; 33(1):103-9. PubMed ID: 22015929
[TBL] [Abstract] [Full Text] [Related]
20. Prognostic significance of he4 expression in pulmonary adenocarcinoma.
Yamashita S; Tokuishi K; Hashimoto T; Moroga T; Kamei M; Ono K; Miyawaki M; Takeno S; Chujo M; Yamamoto S; Kawahara K
Tumour Biol; 2011 Apr; 32(2):265-71. PubMed ID: 20953751
[TBL] [Abstract] [Full Text] [Related]
